Cargando…

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting

Patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA) have exhibited improved overall survival. However, information on AZA in real-world settings is limited. The present study retrospectively analyzed 85 patients with MDS treated with AZA. Complete response was achi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakaya, Aya, Fujita, Shinya, Satake, Atsushi, Nakanishi, Takahisa, Azuma, Yoshiko, Tsubokura, Yukie, Saito, Ryo, Konishi, Akiko, Hotta, Masaaki, Yoshimura, Hideaki, Ishii, Kazuyoshi, Ito, Tomoki, Nomura, Shosaku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956411/ https://www.ncbi.nlm.nih.gov/pubmed/31966063 http://dx.doi.org/10.3892/ol.2019.11225

Ejemplares similares

Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents
por: Nakaya, Aya, et al.
Publicado: (2017)

Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection
por: Nakaya, Aya, et al.
Publicado: (2017)

Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide
por: Ito, Tomoki, et al.
Publicado: (2018)

Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia
por: Hotta, Masaaki, et al.
Publicado: (2018)

Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study
por: Ito, Tomoki, et al.
Publicado: (2018)

Human T-cell Leukemia Virus Type I Associated with an Increased Risk of Primary Malignant Neoplasm
por: Nakaya, Aya, et al.
Publicado: (2018)

Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma
por: Nakaya, Aya, et al.
Publicado: (2016)

Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia
por: Nakaya, Aya, et al.
Publicado: (2018)

Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era
por: Nakaya, Aya, et al.
Publicado: (2017)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
por: Konishi, Akiko, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma
por: Azuma, Yoshiko, et al.
Publicado: (2019)

Retrospective analysis of adolescent and young adult with lymphoma at two cancer facilities in Japan
por: Nakaya, Aya, et al.
Publicado: (2019)

Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era
por: Nakaya, Aya, et al.
Publicado: (2019)

Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
por: Takeyasu, Yuki, et al.
Publicado: (2017)

Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia
por: AZUMA, YOSHIKO, et al.
Publicado: (2016)

Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report
por: FUJITA, YUKIE, et al.
Publicado: (2016)

Myodesopsia is a symptom of central nervous system blast crisis in chronic myeloid leukemia
por: Ishii, Kazuyoshi, et al.
Publicado: (2019)

A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptoms
por: Nakanishi, Takahisa, et al.
Publicado: (2019)

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan
por: Yoshimura, Hideaki, et al.
Publicado: (2017)

Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma
por: Nomura, Shosaku, et al.
Publicado: (2018)

Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review
por: Hotta, Masaaki, et al.
Publicado: (2021)

Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement: A Case Report with Literature Review
por: Nakanishi, Takahisa, et al.
Publicado: (2020)

Efficacy and safety of anagrelide as a first‐line drug in cytoreductive treatment‐naïve essential thrombocythemia patients in a real‐world setting
por: Ito, Tomoki, et al.
Publicado: (2019)

Localized lymphadenopathy with myelodysplastic syndrome associated with tuberculosis
por: Nakaya, Aya, et al.
Publicado: (2019)

Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract
por: Tsubokura, Yukie, et al.
Publicado: (2022)

Six cases of autoimmune acquired coagulation factor VIII deficiency: Single center experience in Japan
por: Konishi, Akiko, et al.
Publicado: (2020)

Therapeutic effect of bortezomib for primary plasma cell leukemia followed by auto/allo stem cell transplantation
por: Ozasa, Ryotaro, et al.
Publicado: (2012)

Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog
por: Natelson, Ethan A., et al.
Publicado: (2013)

Methotrexate-induced myelodysplasia mimicking myelodysplastic syndrome
por: Kawase, Yuuki, et al.
Publicado: (2018)

Copper and Zinc Feud: Is This Myelodysplasia or Myelodysplastic Syndrome?
por: Kumar, Manoj, et al.
Publicado: (2022)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3(mut+) AML ineligible for intensive chemotherapy
por: Wang, Eunice S., et al.
Publicado: (2022)

Primary dural high grade B cell lymphoma mimicking subdural hematoma
por: Nakaya, Aya, et al.
Publicado: (2021)

Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β(1), and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia
por: Nomura, Shosaku, et al.
Publicado: (2018)

Safety and efficacy of azacitidine in myelodysplastic syndromes
por: Vigil, Carlos E, et al.
Publicado: (2010)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
por: Götze, KS, et al.
Publicado: (2009)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Yamamoto, Kazuhito, et al.
Publicado: (2021)

Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes
por: Bezerra, Matheus F., et al.
Publicado: (2022)

Relationship between Altered miRNA Expression and DNA Methylation of the DLK1-DIO3 Region in Azacitidine-Treated Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Myelodysplasia-Related Changes
por: Merkerova, Michaela Dostalova, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l3f5qrvcv1hjnpddmrl6siauf6